Stockscreener 앱 받기
3.56
5.32%
-0.20
전일 마감가:
$3.76
열려 있는:
$3.8
하루 거래량:
20.73M
Relative Volume:
1.15
시가총액:
$1.89B
수익:
$66.41M
순이익/손실:
$-559.78M
주가수익비율:
-2.9612
EPS:
-1.2022
순현금흐름:
$-328.09M
1주 성능:
-6.32%
1개월 성능:
+17.11%
6개월 성능:
-23.61%
1년 성능:
-37.71%
1일 변동 폭
$3.44
$3.80
1주일 범위
$3.44
$4.09
52주 변동 폭
$2.77
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.56 | 1.89B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced? - simplywall.st
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 10 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary - Quartr
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Insider Sell: Blake Borgeson Sells 40,000 Shares of Recursion Ph - GuruFocus
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com - Investing.com India
Recursion Pharmaceuticals director Borgeson sells $158,500 stock - Investing.com
Form 144 RECURSION PHARMACEUTICALS For: 9 July By Investing.com - Investing.com Canada
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires? - Insider Monkey
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Form 144 RECURSION PHARMACEUTICALS For: 8 July By Investing.com - Investing.com Nigeria
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Citi's Biopharma Back to School Conference Summary - Quartr
$Recursion Pharmaceuticals (RXRX.US)$Hey everyone, is this symbol that looks like a 🎲 indicating a buy or a sell? Please help! - Moomoo
Is Recursion (RXRX) Gaining Lasting Strategic Credibility From Its Expanded Russell Index Presence? - simplywall.st
Form 144 RECURSION PHARMACEUTICALS For: 7 July By Investing.com - Investing.com Canada
RXRX: Founder’s 40,000 Class A shares listed; insider sales reported (RXRX) - Stock Titan
Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally - TechStock²
Form 144 RECURSION PHARMACEUTICALS For: 6 July By Investing.com - Investing.com Canada
Insider sells 340,440 RXRX shares (NASDAQ: RXRX) - Stock Titan
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus - TechStock²
Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation - Quiver Quantitative
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock - Investing.com
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com - Investing.com UK
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
RXRX rallies past biotech ETFs as short interest, insider-sale filings shape coming week - TechStock²
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain - Moomoo
RXRXRecursion Pharmaceuticals Inc Volatility & Greeks - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) pops, short interest still much bigger than new founder-sale alert - TechStock²
Form 4 Recursion Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares - Stock Titan
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant - Stock Titan
RXRX Stock Draws ARK Buying As AI Drug Story Builds - timothysykes.com
Christopher C. Gibson lists multiple Class A sales (RXRX) - Stock Titan
Form 144 RECURSION PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares - Stock Titan
Anthropic Launches Claude Science to Enter Life Sciences, AI Drug Discovery Stocks Tumble in Response - NAI500
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value? - simplywall.st
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Jul 07 '26 |
Sale |
3.96 |
40,000 |
158,500 |
6,218,287 |
2.64%
자본화:
|
볼륨(24시간):